Sigma-Aldrich (SIAL) to Acquire BioReliance Holdings in $350M Deal
Tweet
Share
E-mailGet Alerts SIAL Hot Sheet
Join SI Premium – FREE
Sigma-Aldrich Corporation (Nasdaq: SIAL), has signed an agreement to acquire BioReliance Holdings, Inc., a leading provider of global biopharmaceutical testing services, from Avista Capital Partners for $350 million in cash. The acquisition is subject to customary closing conditions, including regulatory clearance, and is expected to close in the first quarter of 2012.
Sigma-Aldrich expects to fund the acquisition with a combination of existing cash and credit facilities.
Morgan Stanley & Co. LLC acted as financial advisor and Bryan Cave LLP served as legal advisor to Sigma-Aldrich for this transaction.
Sigma-Aldrich expects to fund the acquisition with a combination of existing cash and credit facilities.
Morgan Stanley & Co. LLC acted as financial advisor and Bryan Cave LLP served as legal advisor to Sigma-Aldrich for this transaction.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bernstein on whether Hershey (HSY) could eventually step up to buy Mondelez (MDLZ)
- Real and RE/MAX Holdings receive court approval for merger
- LivePerson extends special meeting deadline for SoundHound AI merger vote
Create E-mail Alert Related Categories
Mergers and AcquisitionsRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
